Cell And Gene Therapy Third-Party Logistics Market To Reach $20.04 Billion By 2030

Cell & Gene Therapy Third-Party Logistics Market Growth & Trends

The global cell and gene therapy third-party logistics market is expected to reach USD 20.04 billion by 2030, expanding at a CAGR of 11.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is mainly due to rising demand for cell and gene therapies, which require precise handling, strict temperature controls, and seamless coordination between manufacturers, hospitals, and treatment centers. CGTs are patient-specific, which signifies that a single patient’s cells must be collected, transported, modified, and reinfused within tight timelines. Any failure in logistics can result in the loss of an expensive, potentially life-saving therapy. The personalized nature of CGTs has increased the need for advanced cold chain logistics, with cryogenic storage and ultra-low temperature transportation becoming standard requirements.

In addition, the growing pipeline of CGT clinical trials and commercial approvals encourages logistics providers to scale their capabilities, ensuring that the increasing volume of therapies reaches patients without compromising quality. This shift is compelling biopharmaceutical companies to seek specialized 3PL partners that can handle the complexities of CGT supply chains, ensuring compliance with strict regulatory requirements while optimizing distribution efficiency. Moreover, the growing regulatory support is also one of the factors contributing to market growth. The U.S. FDA, EMA, and other global regulatory bodies impose stringent guidelines on the transportation and storage of CGTs to maintain their potency and safety. Regulatory compliance requires logistics providers to implement Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP) standards, which govern every aspect of supply chain management, from packaging to real-time tracking. Failure to comply can result in rejected shipments, financial losses, and treatment delays for patients.

Furthermore, growing initiatives by the market players, such as partnerships and collaborations, service expansion, product launches, and increasing pipeline products, contribute to market growth. For instance, in March 2025, DHL acquired CryoPDP, a specialist in temperature-controlled logistics for life sciences. The acquisition aims to strengthen the infrastructure for handling advanced therapies. CryoPDP’s expertise in ultra-cold storage and real-time monitoring solutions aligns with DHL’s strategy, providing end-to-end solutions for biopharma companies.

 Request a free sample copy or view report summary: Cell And Gene Therapy Third-Party Logistics Market Report

Cell And Gene Therapy Third-Party Logistics Market Report Highlights

• Based on type, the clinical segment dominated the market due to the increasing number of research and development activities by the market players coupled with the growing number of cell and gene therapies product pipelines.

• Based on the product, cell therapies dominated the market in 2024 due to increasing regulatory approvals and expanding commercialization efforts. The success of CAR-T cell therapies for cancer treatment played a crucial role in this growth, with companies like Novartis, Gilead Sciences, and Bristol Myers Squibb driving widespread adoption.

• Based on temperature range, ambient storage held the largest market share in 2024due to the increasing demand for gene therapies, biologics, and regenerative medicine products that do not require ultra-low or cryogenic temperatures.

• Based on the therapeutic area, the oncology segment dominated the market in 2024due to the rapid adoption of advanced therapies for treating various cancers, particularly hematologic and solid tumors.

• Based on end use, biopharmaceutical companies held the largest market share in 2024due to their high reliance on temperature-controlled storage and transportation for biologics and specialty drugs.

Cell And Gene Therapy Third-Party Logistics Market Segmentation

For this report, Grand View Research has segmented the global healthcare cold chain third-party logistics market based on type, product, temperature range, therapeutic area, end-use, and region:

Cell & Gene Therapy Third-Party Logistics Type Outlook (Revenue, USD Million; 2018 - 2030)

• Clinical

• Commercial

Cell & Gene Therapy Third-Party Logistics Product Outlook (Revenue, USD Million; 2018 - 2030)

• Cell Therapies

• Gene Therapies

Cell & Gene Therapy Third-Party Logistics Temperature Range Outlook (Revenue, USD Million; 2018 - 2030)

• Ambient Storage

• Refrigerated Storage

• Ultra-Low Temperature Storage

• Cryogenic Storage

Cell & Gene Therapy Third-Party Logistics Therapeutic Area Outlook (Revenue, USD Million; 2018 - 2030)

• Oncology

• Neurology

• Cardiovascular Diseases

• Ophthalmology

• Infectious Diseases

• Others

Cell & Gene Therapy Third-Party Logistics End-use Outlook (Revenue, USD Million; 2018 - 2030)

• Biopharmaceutical Companies

• CDMOs/CMOs

• Others

Cell & Gene Therapy Third-Party Logistics Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Cell & Gene Therapy Third-Party Logistics Market

• Cencora Corporation

• Cardinal Health

• McKesson Corporation

• EVERSANA

• Knipper Health

• Arvato SE

• DHL

• FedEx

• Kuehne and Nagel

• United Parcel Service of America, Inc.